BioMarin Pharmaceutical (BMRN) AI Stock Analysis

• Market Cap: $10.44B
• Dividend Yield: N/A
• Average Volume (3M): 2.00M
• Price to Earnings (P/E): 16.1
• Beta (1Y): 0.43
• Revenue Growth: 17.38%
• EPS Growth: 153.58%
• Country: US
• Employees: 3,040
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.23
• Shares Outstanding: 192,014,600
• 10 Day Avg. Volume: 2,286,974
• 30 Day Avg. Volume: 1,996,489
• PEG Ratio: 0.19
• Price to Book (P/B): 2.21
• Price to Sales (P/S): 4.38
• P/FCF Ratio: 26.27
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 3.27
• Enterprise Value/Gross Profit: 4.11
• Enterprise Value/Ebitda: 11.19
• 1Y Price Target: $98.59
• Price Target Upside: 81.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 24

• Rating: 76 Outperform
• Price Target: $64.00 ▲(17.73% Upside)

BioMarin Pharmaceutical's strong financial performance and positive earnings call are the primary drivers of its stock score. While technical indicators suggest a bearish trend, the company's solid fundamentals and strategic initiatives provide a positive outlook. The valuation is reasonable, though the lack of a dividend yield may deter some investors.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective product adoption, supporting long-term business expansion and sustainability.

Pipeline Progress

Advancements in the pipeline, like BMN 333, demonstrate BioMarin's commitment to innovation and potential for future product launches, enhancing competitive positioning.

Cash Flow Management

Strong cash flow growth and management provide financial flexibility for strategic investments and operational stability, supporting long-term growth.

Negative Factors

Increased Operating Expenses

Rising operating expenses could pressure margins and profitability, potentially impacting financial performance if not offset by revenue growth.

Potential Lower Profitability in Q3

Anticipated lower profitability in Q3 due to increased expenses may affect short-term financial results, posing a challenge to maintaining margin improvements.

VOXZOGO Revenue Guidance Adjustment

Adjusting VOXZOGO's revenue guidance suggests potential challenges in meeting sales expectations, which could impact overall revenue targets and investor confidence.

BioMarin Pharmaceutical Business Overview & Revenue Model

Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

How the Company Makes Money

BioMarin generates revenue primarily through the sale of its pharmaceutical products, which are targeted at rare diseases. Key revenue streams include the sale of its approved therapies, such as Vimizim (elosulfase alfa), Brineura (cerliponase alfa), and Kuvan (sapropterin dihydrochloride). Additionally, the company engages in partnerships and collaborations with other pharmaceutical and biotechnology firms to enhance its research capabilities and expand its market reach. These partnerships may involve co-development agreements, licensing fees, and milestone payments that contribute to BioMarin's earnings. The company's focus on rare diseases often allows it to command higher prices for its specialized treatments, further bolstering its revenue.

BioMarin Pharmaceutical Financial Statement Overview

Summary

BioMarin Pharmaceutical demonstrates solid financial health with strong revenue growth, improved profitability, and effective cash flow management. The balance sheet remains robust with low leverage, supporting long-term stability. While operational margins show slight pressure, the company's financial trajectory is positive, positioning it well for future growth.

Income Statement

BioMarin Pharmaceutical has shown a strong revenue growth trajectory with a 3.97% increase in TTM, supported by a robust gross profit margin of 79.50%. The net profit margin has improved significantly to 21.52% in TTM, indicating enhanced profitability. However, the EBIT margin slightly decreased to 17.84%, suggesting some operational cost pressures.

Balance Sheet

The company's balance sheet is stable with a low debt-to-equity ratio of 0.10, reflecting conservative leverage. Return on equity has improved to 11.48% in TTM, showcasing effective utilization of equity. The equity ratio stands at 80.82%, indicating a strong equity position relative to total assets.

Cash Flow

BioMarin's cash flow performance is commendable with an 11.49% growth in free cash flow in TTM. The operating cash flow to net income ratio of 1.12 indicates efficient cash generation relative to net income. The free cash flow to net income ratio of 0.90 further underscores strong cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.06B	2.85B	2.42B	2.10B	1.85B	1.86B
Gross Profit	2.44B	2.27B	1.89B	1.59B	1.38B	1.34B
EBITDA	895.24M	650.86M	310.28M	267.51M	48.03M	13.41M
Net Income	657.24M	426.86M	167.65M	141.56M	-64.08M	854.03M
Balance Sheet
Total Assets	7.46B	6.99B	6.84B	6.38B	6.00B	5.85B
Cash, Cash Equivalents and Short-Term Investments	1.43B	1.14B	1.07B	1.29B	1.01B	1.07B
Total Debt	603.87M	602.71M	1.10B	1.09B	1.09B	1.09B
Total Liabilities	1.43B	1.33B	1.89B	1.77B	1.74B	1.74B
Stockholders Equity	6.03B	5.66B	4.95B	4.60B	4.27B	4.11B
Cash Flow
Free Cash Flow	691.43M	475.42M	51.65M	44.36M	185.31M	-52.15M
Operating Cash Flow	766.77M	572.84M	159.26M	175.90M	304.54M	85.36M
Investing Cash Flow	19.42M	136.49M	-111.24M	-20.03M	-366.31M	-53.62M
Financing Cash Flow	-539.65M	-526.45M	-18.73M	-18.65M	-48.00K	181.12M

BioMarin Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 54.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Negative. The current price of 54.36 is below the 20-day moving average (MA) of 56.46, below the 50-day MA of 57.59, and below the 200-day MA of 61.78, indicating a bearish trend. The MACD of -1.03 indicates Positive momentum. The RSI at 41.72 is Neutral, neither overbought nor oversold. The STOCH value of 37.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRN.

BioMarin Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	82 Outperform	17.49B	14.00	22.13%	―	23.25%	64.46%
INCY	80 Outperform	16.90B	19.67	20.88%	―	18.87%	1088.27%
EXEL	77 Outperform	10.80B	19.23	29.62%	―	10.73%	81.66%
UTHR	77 Outperform	18.89B	16.30	18.55%	―	17.62%	19.89%
BMRN	76 Outperform	$10.44B	16.10	11.62%	―	17.38%	153.58%
ASND	61 Neutral	11.97B	-39.79	357.68%	―	55.77%	46.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BioMarin Pharmaceutical Corporate Events

BioMarin Announces Resignation of Chief Accounting Officer

On August 5, 2025, BioMarin Pharmaceutical announced the resignation of Erin Burkhart, their Group Vice President and Chief Accounting Officer, effective September 2, 2025. The company will search for her successor, and in the interim, Brian Mueller, the Executive Vice President and Chief Financial Officer, will assume her responsibilities without additional compensation.

BioMarin Expands Board with New Director Appointment

On July 30, 2025, BioMarin Pharmaceutical‘s Board of Directors expanded from ten to eleven members, appointing Ian T. Clark effective August 1, 2025. Mr. Clark joins the Audit and Science and Technology Committees, receiving standard director fees and a $400,000 restricted stock unit grant. This strategic move aims to strengthen BioMarin’s governance and oversight, potentially enhancing its industry positioning and stakeholder confidence.